(Q38212007)

31 August 2017

Canagliflozin: a review of its use in patients with type 2 diabetes mellitus (English)

1 reference

31 August 2017

1 reference

1

Greg L Plosker

1 reference

PubMed ID

24831734

31 August 2017

language of work or name

1 reference

1 May 2014

1 reference

31 August 2017

1 reference

31 August 2017

74

1 reference

31 August 2017

7

1 reference

31 August 2017

807-824

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-014-0225-5

31 August 2017

0 references

cites work

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Towards better understanding of the contributions of overwork and glucotoxicity to the beta-cell inadequacy of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

miRNA-30a-5p-mediated silencing of Beta2/NeuroD expression is an important initial event of glucotoxicity-induced beta cell dysfunction in rodent models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Canagliflozin: effects in overweight and obese subjects without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Dapagliflozin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Management of type 2 diabetes: new and future developments in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0225-5

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

21 January 2018

1 reference

12 December 2020

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

1 reference

12 December 2020

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis

1 reference

12 December 2020

Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?

1 reference

12 December 2020

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

1 reference

12 December 2020

10.1007/S40265-014-0225-5

Identifiers

DOI

1 reference

PubMed ID

24831734

Dimensions Publication ID

31 August 2017

0 references

1 reference

PubMed ID

24831734